FDA expands access to promising drug for pancreatic cancer

FDA grants early access to promising drug for pancreatic cancer

Patients with one of the deadliest cancers have been pleading for this yet-unapproved treatment that may prolong their lives.

For pancreatic cancer, the FDA grants early access to the experimental drug daraxonrasib

The federal Food and Drug Administration said Friday it will grant some patients early access to Revolution Medicines' experimental pancreatic cancer drug daraxonrasib.The drug — which former U.S. Sen. Ben Sasse, R-Nebraska, is being treated with for his Stage 4 pancreatic cancers — hasn’t been approved by the FDA. But the FDA told the Redwood City, California, manufacturer it can begin an "expanded access treatment protocol" for some patients w…

FDA expands access to promising drug for pancreatic cancer

More patients will be able to take the pill while it is under review, as the agency said it recognizes the dire need for a drug to fight one of the deadliest cancers.

FDA expands access to pancreatic cancer drug helping patients like Ben Sasse

Former Sen. Ben Sasse, 54, called daraxonrasib "a miracle drug" that was allowing him to live longer and with less pain.

FDA grants early access to promising pancreatic cancer drug

The Food and Drug Administration said Friday that it would permit some patients with deadly pancreatic cancer to receive early access to a promising, highly coveted drug.

FDA green lights early access to pancreatic cancer drug, daraxonrasib

The FDA said it will grant some patients early access to Revolution Medicines' experimental pancreatic cancer drug daraxonrasib.